Why is Mangalam Drugs falling/rising?

As of 19-Sep, Mangalam Drugs and Organics Ltd is experiencing a price increase, currently trading at 75.90, which reflects a rise of 0.9 or 1.2%. Today's performance indicates that the stock has outperformed its sector by 0.93%. However, despite this short-term gain, the stock has shown a significant decline over the past month, down 6.76%, and a staggering 40.28% over the past year. The company has reported an operating loss and a weak long-term fundamental strength, with a poor EBIT to Interest ratio of 1.73 and a negative PAT of Rs -13.74 crore. Additionally, the stock is trading at a discount compared to its peers, but its profits have fallen drastically by 399.4%, which raises concerns about its future performance.
In the broader market context, the stock's short-term return of 1.20% over the past week slightly outpaces the Sensex, which has increased by 0.88%. However, the stock's long-term performance has been consistently poor, with a decline of 48.01% over the last three years compared to a 39.71% gain in the benchmark. This consistent underperformance, coupled with falling investor participation and negative financial results over the last two quarters, suggests that while there may be short-term fluctuations, the overall outlook for Mangalam Drugs remains weak.